Sensei Biotherapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Sensei Biotherapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($4.57M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($4.94M) | Aug 5, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($4.94M) | Nov 14, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($6.86M) | Aug 5, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($6.86M) | Nov 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($6.86M) | May 6, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($7.25M) | Nov 14, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($7.14M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($7.14M) | Aug 5, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($7.99M) | Nov 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($7.99M) | May 6, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($7.99M) | Aug 5, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($7.12M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($9.39M) | Aug 6, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($9.39M) | Nov 14, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($10.18M) | Nov 14, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($10.18M) | May 9, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($10.18M) | Aug 6, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($13.42M) | Nov 7, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($10.54M) | Aug 3, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($4.85M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($5.21M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($7.27M) | May 6, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($7.82M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($7.79M) | Aug 5, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($8.73M) | May 6, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($7.74M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($10.18M) | Aug 6, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($11.01M) | May 9, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($13.94M) | Nov 7, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($10.71M) | Aug 3, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($12.49M) | May 9, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($10.32M) | Nov 8, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($9.78M) | Aug 9, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($7.97M) | May 10, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($5.36M) | Nov 10, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($4.91M) | Aug 11, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($4.10M) | May 13, 2021 |